Search - tctmd.com

Displaying 841 - 860 of 1227

Sort: Relevancy | Date

Presentation TCT 2017

Germany Comments: How Would I Treat This Case and Why?

Presenter: Petr Kala, Jochen Wöhrle, Thomas Walther

October 30, 2017

Presentation TCT 2017

Primary Prevention in High Risk Patients II: THEMIS

Presenter: Bernard J. Gersh, Robert A. Harrington

October 30, 2017

Presentation TCT 2017

Primary Prevention In High Risk Patients I: REPRIEVE

Presenter: Bernard J. Gersh, Robert A. Harrington, Pamela S. Douglas

October 30, 2017

Presentation TCT 2017

Czech Republic Comments: How Would I Treat This Case and Why?

Presenter: Petr Kala, Jochen Wöhrle, Marian Branny

October 30, 2017

Presentation TCT 2017

Slovakia Presents: Current Knowledge Impact of Coronary Artery Disease on TAVR Management and Outcomes

Presenter: Petr Kala, Jochen Wöhrle, Martin Hudec

October 30, 2017

Presentation TCT 2017

Tricuspid Valve Disease and TTV Repair and Replacement: Progress and Obstacles

Presenter: Russell A. Brandwein

October 30, 2017

Presentation TCT 2017

Predicting The Future: Will the Ongoing COAPT Trial Change How We Treat Patients With Secondary MR in Heart Failure?

Presenter: David H. Adams, Ted Feldman, Gilles Dreyfus

October 30, 2017

Presentation TCT 2017

Mitral Valve Disease and TMV Repair and Replacement: Progress and Obstacles

Presenter: Russell A. Brandwein, Elizabeth M. Perpetua

October 30, 2017

Presentation TCT 2017

Predicting the Future: Will the Ongoing TAVR UNLOAD and Early TAVR Trials Change the Threshold for TAVR in Moderate and Asymptomatic Aortic Stenosis?

Presenter: David H. Adams, Ted Feldman, Allan Schwartz

October 30, 2017

Presentation TCT 2017

Predicting the Future: Will the Ongoing GALILEO and ENVISAGE AF Trials Change How We Anticoagulate Patients After TAVR?

Presenter: David H. Adams, Ted Feldman, Vinod H. Thourani

October 30, 2017

Presentation TCT 2017

TAVR Patient Journey V: Addressing Complications and Follow-up

Presenter: Martina Kelly Speight, Amy E. Simone

October 30, 2017

Presentation TCT 2017

Predicting the Future: Will the Ongoing LOW RISK TAVR Trials Change How We Treat Low Surgical Risk Patients With Aortic Stenosis?

Presenter: David H. Adams, Ted Feldman, Craig R. Smith

October 30, 2017

Presentation TCT 2017

TAVR Patient Journey IV: The Hospital Experience

Presenter: Martina Kelly Speight, Sandra Lauck

October 30, 2017

Presentation TCT 2017

TAVR should be reserved for intermediate and higher-risk tricuspid valve aortic stenosis!

Presenter: A. Pieter Kappetein

October 30, 2017

Presentation TCT 2017

Were ready to treat bicuspid valve and lower-risk tricuspid valve aortic stenosis!

Presenter: Susheel K. Kodali

October 30, 2017

Presentation TCT 2017

TAVR Patient Journey III: Behind the Scenes

Presenter: Martina Kelly Speight, Sarah Clarke

October 30, 2017

Presentation TCT 2017

TAVR Patient Journey II: Imaging Assessment

Presenter: Martina Kelly Speight, João L Cavalcante

October 30, 2017

Presentation TCT 2017

TAVR Patient Journey I: Initial Evaluation

Presenter: Martina Kelly Speight, Patricia Keegan

October 30, 2017

Presentation TCT 2017

Valvular Heart Disease Interventions: Take-home Messages

Presenter: Habib Gamra, Mohamed Ahmed Sobhy, Graham A. Cassel, E. Murat Tuzcu

October 29, 2017

Presentation TCT 2017

Valvular Heart Disease Interventions: Take-home Messages

Presenter: Habib Gamra, Mohamed Ahmed Sobhy, Graham A. Cassel, E. Murat Tuzcu

October 29, 2017

Advertisement

Germany Comments: How Would I Treat This Case and Why?

Primary Prevention in High Risk Patients II: THEMIS

Primary Prevention In High Risk Patients I: REPRIEVE

Czech Republic Comments: How Would I Treat This Case and Why?

Slovakia Presents: Current Knowledge Impact of Coronary Artery Disease on TAVR Management and Outcomes

Tricuspid Valve Disease and TTV Repair and Replacement: Progress and Obstacles

Predicting The Future: Will the Ongoing COAPT Trial Change How We Treat Patients With Secondary MR in Heart Failure?

Mitral Valve Disease and TMV Repair and Replacement: Progress and Obstacles

Predicting the Future: Will the Ongoing TAVR UNLOAD and Early TAVR Trials Change the Threshold for TAVR in Moderate and Asymptomatic Aortic Stenosis?

Predicting the Future: Will the Ongoing GALILEO and ENVISAGE AF Trials Change How We Anticoagulate Patients After TAVR?

TAVR Patient Journey V: Addressing Complications and Follow-up

Predicting the Future: Will the Ongoing LOW RISK TAVR Trials Change How We Treat Low Surgical Risk Patients With Aortic Stenosis?

TAVR Patient Journey IV: The Hospital Experience

TAVR should be reserved for intermediate and higher-risk tricuspid valve aortic stenosis!

Were ready to treat bicuspid valve and lower-risk tricuspid valve aortic stenosis!

TAVR Patient Journey III: Behind the Scenes

TAVR Patient Journey II: Imaging Assessment

TAVR Patient Journey I: Initial Evaluation

Valvular Heart Disease Interventions: Take-home Messages

Valvular Heart Disease Interventions: Take-home Messages

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content